Literature DB >> 26945902

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.

Melanie Ruf1, Holger Moch1, Peter Schraml1.   

Abstract

In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD-L1. In vitro analysis provided evidence that both reconstitution of pVHL and silencing of HIF2α, but not of HIF1α, lead to reduced PD-L1 expression. The strong correlation of expression between the HIF2α-specific HIF target Glut1 and PD-L1 confirmed this finding in ccRCC cell lines and tissue. Soluble PD-L1 levels remained constant in the sera of ccRCC patients regardless of the PD-L1 expression status in their tumors. In conclusion, our data suggest PD-L1 as HIF2α target, which is upregulated in pVHL deficient ccRCC. The combination of PD-L1 targeting drugs with HIF inhibiting agents may be an additional option for the treatment of ccRCC.
© 2016 UICC.

Entities:  

Keywords:  HIF; PD-L1; ccRCC; pVHL

Mesh:

Substances:

Year:  2016        PMID: 26945902     DOI: 10.1002/ijc.30077

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  67 in total

Review 1.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

Review 2.  Exercise as Adjunct Therapy in Cancer.

Authors:  Kathleen A Ashcraft; Allison Betof Warner; Lee W Jones; Mark W Dewhirst
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 3.  HIF Inhibitors: Status of Current Clinical Development.

Authors:  Jaleh Fallah; Brian I Rini
Journal:  Curr Oncol Rep       Date:  2019-01-22       Impact factor: 5.075

4.  Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Authors:  Amber J Giles; Shuyu Hao; Michelle Padget; Hua Song; Wei Zhang; John Lynes; Victoria Sanchez; Yang Liu; Jinkyu Jung; Xiaoyu Cao; Rika Fujii; Randy Jensen; David Gillespie; Jeffrey Schlom; Mark R Gilbert; Edjah K Nduom; Chunzhang Yang; John H Lee; Patrick Soon-Shiong; James W Hodge; Deric M Park
Journal:  JCI Insight       Date:  2019-10-17

5.  Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Authors:  Kyoichi Kaira; Tetsuya Higuchi; Ichiro Naruse; Yukiko Arisaka; Azusa Tokue; Bolag Altan; Satoshi Suda; Akira Mogi; Kimihiro Shimizu; Noriaki Sunaga; Takeshi Hisada; Shigehisa Kitano; Hideru Obinata; Takehiko Yokobori; Keita Mori; Masahiko Nishiyama; Yoshihito Tsushima; Takayuki Asao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-21       Impact factor: 9.236

Review 6.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

7.  Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

Authors:  Yingming Zhu; Yuanwei Zang; Fen Zhao; Zhenxiang Li; Jianbo Zhang; Liang Fang; Minghuan Li; Ligang Xing; Zhonghua Xu; Jinming Yu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 8.  The importance of exosomal PDL1 in tumour immune evasion.

Authors:  Dhouha Daassi; Kathleen M Mahoney; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2020-01-21       Impact factor: 53.106

Review 9.  PD-1/PD-L1 blockade in renal cell cancer.

Authors:  Kathryn E Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Clin Immunol       Date:  2016-07-28       Impact factor: 4.473

Review 10.  Improving immune-vascular crosstalk for cancer immunotherapy.

Authors:  Yuhui Huang; Betty Y S Kim; Charles K Chan; Stephen M Hahn; Irving L Weissman; Wen Jiang
Journal:  Nat Rev Immunol       Date:  2018-01-15       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.